Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 7/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | ROS1 | P08922 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19639590 | 0.92 | EGFR (0.50) | EGFRMKNK2MKNK1JAK2ROS1 | |
| SCHEMBL30885811 | 0.89 | EGFR (0.48) | EGFRMKNK2MKNK1JAK2ROS1 | |
| SCHEMBL19639587 | 0.89 | EGFR (0.48) | EGFRMKNK2MKNK1JAK2ROS1 | |
| SCHEMBL32671769 | 0.86 | MKNK1 (0.65) | EGFRMKNK2MKNK1JAK2ROS1 | |
| SCHEMBL14660648 | 0.86 | MKNK1 (0.65) | EGFRMKNK2MKNK1JAK2ROS1 | |
| SCHEMBL29555980 | 0.86 | MKNK1 (0.65) | EGFRMKNK2MKNK1JAK2ROS1 | |
| SCHEMBL19639595 | 0.86 | EGFR (0.56) | EGFR | |
| Hydrochloric Acid SCHEMBL31218386 | 0.86 | MKNK1 (0.64) | EGFRMKNK2MKNK1JAK2ROS1 | |
| SCHEMBL28363233 | 0.85 | MKNK2 (0.63) | EGFRMKNK2MKNK1 | |
| SCHEMBL29589168 | 0.85 | MKNK2 (0.63) | EGFRMKNK2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049460-B2 | EGFR inhibitor compounds | RECURIUM IP HOLDINGS, LLC (US) | 2024-07-30 | — | — | US | disclosed |
| EP-3464275-B1 | EGFR INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20210395230-A1 | EGFR INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS, LLC (US) | 2021-12-23 | — | — | US | disclosed |
| US-20200181120-A1 | EGFR INHIBITOR COMPOUNDS | KALYRA PHARMACEUTICALS, INC. | 2020-06-11 | — | — | US | disclosed |
| EP-3464275-A1 | EGFR INHIBITOR COMPOUNDS | Zeno Royalties & Milestones, LLC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20170342055-A1 | EGFR INHIBITOR COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2017-11-30 | — | — | US | disclosed |
| WO-2017205459-A1 | EGFR INHIBITOR COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181120-A1 | EGFR INHIBITOR COMPOUNDS | EGFR, ERBB2, ERBB3 | EGFR 1/4885MKNK2 357/4885MKNK1 362/4885 |
| US-20170342055-A1 | EGFR INHIBITOR COMPOUNDS | EGFR, ERBB2, ERBB3 | EGFR 1/4885MKNK2 357/4885MKNK1 362/4885 |
| US-12049460-B2 | EGFR inhibitor compounds | EGFR, ERBB2, ERBB3 | EGFR 1/4885MKNK2 528/4885MKNK1 495/4885 |
| US-20210395230-A1 | EGFR INHIBITOR COMPOUNDS | EGFR, ERBB2, ERBB3 | EGFR 1/4885MKNK2 357/4885MKNK1 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.